Advanced HCC patient who did not respond to standard-of-care therapy with sorafenib, was enrolled in the study.
GenSpera CEO and president Craig Dionne said, "The scientific rationale for testing G-202 in HCC is very high and we are pleased with how readily the clinical community has embraced its development for this patient population."
GenSpera’s technology platform integrates cytotoxin (thapsigargin) with a prodrug delivery system.
Thapsigargin kills cells irrespective of the cell division rate and prodrug delivery system facilitates drug release within the tumor.
G-202 was well-tolerated, with prolonged disease stabilization in several hepatocellular carcinoma patients in Phase Ib program conducted in solid tumor patients.